11 results about "TOFACITINIB CITRATE" patented technology

The invention belongs to the technical field of medicine detection, and particularly relates to a GCMS (Gas Chromatography Mass Spectrometry) detection method for ethyl cyanoacetate in tofacitinib citrate. Respectively injecting the blank solution, the reference solution and the test solution into a GCMS (Gas Chromatography Mass Spectrometer), recording a spectrogram, and calculating the content of ethyl cyanoacetate in tofacitinib citrate by adopting an external standard method; wherein the GCMS conditions comprise a chromatographic column, the column temperature of the chromatographic column is kept at 40 DEG C for 1 min, the temperature is increased to 240 DEG C at the heating rate of 15 DEG C / min, and the temperature is kept for 1 min. The method can accurately and quantitatively detect the content of ethyl cyanoacetate in tofacitinib citrate, and is simple to operate, high in precision, good in stability and good in reproducibility.

The invention provides a tofacitinib citrate sustained-release tablet, which is composed of a sustained-release tablet core and a coating layer, the sustained-release tablet core is prepared by uniformly mixing a solid dispersion and pharmaceutically acceptable auxiliary materials and then tabletting, the tofacitinib citrate sustained release tablet is characterized in that the solid dispersion is prepared from tofacitinib citrate, acrylic resin E and isomaltitol by utilizing a solvent evaporation method, and the coating layer comprises polyvinylpyrrolidone and tert-butyl p-hydroxyanisole. The prepared tofacitinib citrate tablet core particles are high in density, good in flowability and good in compressibility; the prepared tofacitinib citrate sustained release tablet is stable in quality, simple and feasible in process and suitable for large-scale production.

The present application provides a kind of tofacitinib citrate sustained-release preparation, which is composed of tablet core, sustained-release layer coating and color layer coating, and the sustained-release layer coating has drug release small holes. By adjusting the composition of osmotic pressure forming agent and its dosage ratio with sustained-release agent, further optimizing the composition and coating weight of sustained-release layer coating, not only the defect of slow dissolution rate after long-term storage when using sorbitol as osmotic pressure forming agent alone is avoided, but also the initial release rate of tofacitinib citrate sustained-release tablet is improved, and slow and sustained release can be maintained for 6 hours, the drug release is more complete, the blood drug concentration is kept at a uniform and stable level for a long time, the fluctuation of blood drug concentration during the interval of administration is reduced, the bioavailability is further improved, the adverse reactions are reduced, and the clinical efficacy and safety are protected.

The invention belongs to the technical field of medical preparations and pharmaceutical preparations, and particularly relates to a method for improving the stability of citric acid tofacitinib oral liquid and the citric acid tofacitinib oral liquid. The oral liquid takes water as a solvent, contains citric acid tofacitinib, sodium benzoate and ethylenediamine di-o-phenyl sodium acetate, and the pH is regulated to 3.3-4.3 through a pH regulator. The sodium ethylenediamine diphenylacetate in the tofacitinib citrate oral liquid can synergistically inhibit the generation of impurities, block the degradation path of a main drug, stabilize the content of a preservative, significantly reduce the increase of impurities in acceleration and long-term storage, maintain the stability of the content and pH of the main drug, and effectively guarantee the product quality and efficacy.

The application discloses a tofacitinib citrate sustained-release tablet and a preparation method and application thereof. The tofacitinib citrate sustained-release tablet comprises a tablet core and a coating film, and the tablet core comprises the following components in parts by weight: tofacitinib citrate 18 parts, a skeleton material 10-60 parts, a binder 1-10 parts, a filling agent 10-90 parts and a lubricant 1-3 parts. The coating film comprises the following components in parts by weight: hydroxypropyl methyl cellulose 20-30 parts, a plasticizer 1-5 parts, a solid binding peptide 1-5 parts and L-lactide 1-5 parts. The tofacitinib citrate sustained-release tablet of the application can not only achieve the purpose of delayed release in the body, but also greatly improve the bioavailability of the drug. Due to the improvement of the bioavailability of the drug, the dosage can be reduced, the same therapeutic effect can be achieved, and the incidence of adverse reactions can be reduced in clinical application.

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to a method for detecting methyl tert-butyl ether and triethylamine in tofacitinib citrate. Respectively detecting the blank solution, the reference solution and the test solution by headspace gas chromatography, recording chromatograms, and quantitatively analyzing methyl tert-butyl ether and triethylamine in the test solution according to an external standard method; wherein a preparation method of the test solution comprises the following steps: precisely weighing 0.1 g of a tofacitinib citrate sample, putting the tofacitinib citrate sample into a 20ml headspace bottle, adding 2ml of N-methyl pyrrolidone and 0.28 ml of a sodium hydroxide solution with the concentration of 100mg / ml, and sealing. The method realizes effective separation and quantitative detection of methyl tert-butyl ether and triethylamine in tofacitinib citrate, is high in sensitivity, good in repeatability and high in accuracy, makes up for the deficiency of research on methyl tert-butyl ether and triethylamine in tofacitinib citrate, and improves clinical medication safety.

The invention discloses a citric acid tofacitinib osmotic pump sustained-release tablet, which comprises a citric acid tofacitinib tablet core and a sustained-release coating layer coated on the surface of the citric acid tofacitinib tablet core, the citric acid tofacitinib tablet core contains a waxy framework material, and the sustained-release coating layer contains a sustained-release membrane material and a pore-foaming agent; the slow-release membrane material is composed of eudragit RL and eudragit RS; the pore-foaming agent is a water-soluble pore-foaming agent. The invention also discloses a preparation method of the tofacitinib citrate osmotic pump sustained release tablet, which comprises the following steps: uniformly mixing the components of the tablet core, and tabletting to obtain the tablet core; coating the tablet core, preserving heat and curing to obtain the tofacitinib citrate osmotic pump sustained release tablet. According to the invention, the corrosion controlled release of the waxy framework material and the controlled release coating layer are hierarchically coupled, so that the drug release stability is obviously improved, the tolerance to the change of the gastrointestinal tract physiological environment is stronger, and the dissolution of the drug is not reduced after long-term storage.

The invention provides a preparation method of a tofacitinib citrate intermediate, and belongs to the technical field of pharmaceutical chemicals. According to the preparation method, 3-halogenated-4-methylpyridine is taken as a raw material, and the (3R, 4R)-1-benzyl-3-methylamino-4-methyl-piperidine dihydrochloride is prepared through nucleophilic substitution, benzyl halide protection, hydroboron reduction, chiral resolution, dissociation and salification. According to the invention, the boron hydride is used as a reducing agent, and a pyridine ring of the 1-benzyl-3-methylamino-4-methylpyridine hydrochloride is reduced into a piperidine ring, so that the production cost is reduced. The synthesis method is mild in reaction condition, simple to operate and suitable for large-scale industrial production.

The invention provides a preparation method of tofacitinib citrate, and belongs to the technical field of pharmaceutical chemicals. Formic acid and ammonium formate are used as hydrogen donors, transfer hydrogenation is carried out under catalysis of the noble metal catalyst, reaction safety is improved, use of high-pressure hydrogen and high-pressure operation risks are thoroughly avoided, special pressure-resistant equipment is not needed, only a conventional reaction kettle is needed, and equipment investment and safety control cost are greatly reduced.

The invention discloses a tofacitinib citrate tablet and a preparation process thereof, and belongs to the technical field of pharmaceutical preparations. According to the tofacitinib citrate tablet, tofacitinib citrate is taken as an effective component and matched with a filling agent, a stable dissolution promoter, a disintegrating agent, an adhesive and a lubricating agent, and a coating material can be selectively added; wherein the stable dissolution promoter is a combination of polyethylene glycol 4000, glycine and ethyl maltol. The preparation process comprises the following steps: pretreatment of the active ingredients, preparation of the stable dissolution promoter, wet granulation, tabletting and optional coating. The tofacitinib citrate tablet effectively solves the technical problems of insufficient stability and poor dissolution performance of the existing tofacitinib citrate tablet by optimizing the component matching, especially the synergistic effect of the specific ternary stable dissolution promoting agent combination, so that the preparation can be quickly and fully dissolved out in different pH environments, can resist the influence of severe storage environments, and can be used for preparing the tofacitinib citrate tablet. The drug degradation is reduced, and the medication safety and the clinical curative effect are guaranteed.

The application discloses a detection method of raw material drug particle size and particle size distribution of tofacitinib citrate, and comprises the following steps: taking tofacitinib citrate raw material drug to be detected, adding Span 80-n-hexane solution as a dispersing agent, ultrasonic stirring until uniform dispersion, and then detecting the prepared sample by using a wet laser diffraction method. Through a large number of experiments, the Span 80-n-hexane solution is specifically selected as the dispersing agent to prepare a stable test suspension, so that the problem that when tofacitinib citrate is detected by using the wet method, the conventional solvent is used as the dispersing agent, the dispersion system is unstable, the light shielding degree rapidly decreases, and the sample particle size cannot be accurately detected is solved, and the method has important significance in the research and production process of tofacitinib citrate related preparations.